#Deucravacitinib #Tyk2i in active #PsA to 52weeks #PBO was crossed over at 16weeks Ongoing improvement for high bar outcomes ex % in #minimal #disease #activity #MDA #Xray #progression was reduced with real data (not imputed) #ACR2025 @RheumNow @ACRheum https://t.co/kAMym2x8HQ